Cirrhosis
The Latest
New findings 'expose a critical blind spot in liver disease classification'
-
by Julia Cipriano
Routine underreporting of consumption means many patients are being misclassified as MASLD.
MRI techniques shown to improve cirrhosis diagnosis
-
by Doug Brunk
MR elastography found to provide detailed, noninvasive staging even in patients with advanced disease.
MASLD fibrosis significantly drives HCC risk, study finds
-
by Doug Brunk
Large patient-level meta-analysis clarifies how fibrosis stage shapes liver cancer risk.
FDA approves linerixibat for cholestatic pruritus in PBC
-
by Doug Brunk
Linerixibat “is an added therapy that's mechanistically different from what we have, and therefore I think that it's going to be used."
AGA updates MASLD care pathway
-
by Doug Brunk
A two-tier strategy is recommended using noninvasive tests to identify patients who require specialty evaluation.
Steroids show modest 28-day benefit in severe alcohol-associated hepatitis
-
by Doug Brunk
Steroids improve early survival in severe alcohol-associated hepatitis — but long-term benefit remains uncertain.
Pediatric MASLD tied to early morbidity
-
by Doug Brunk
Review details rising prevalence and early fibrosis risk.
Endohepatology expands clinical reach
-
by Doug Brunk
Review details performance data, comparative trials, and persistent gaps as EUS moves deeper into hepatology practice.
Endoscopic ultrasound pushes beyond biopsy in diagnostics
-
by Doug Brunk
Review highlights advances that expand endoscopic ultrasound into precision diagnostics and personalized therapy across pancreatic and liver diseases.
Combination therapy shows promise for hepatitis D in phase 2 trial
-
by Amy Pfeiffer
"Tobevibart and elebsiran have complementary mechanisms of action."
Global MASH costs set to double by 2040
-
by Doug Brunk
A multinational modeling study projects sharp rises in advanced liver disease, deaths and health care spending tied to MASH across nine countries.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
Tiny plastics may harm gut and liver health, review finds
-
by Doug Brunk
“Our aim was to start conversations between clinicians and their patients about this emerging risk,” Dr. Priyata Dutta explained.
ACA expansion linked to better liver disease outcomes
-
by Doug Brunk
The analysis is believed to be the first of its kind.
Cirrhosis, age may shape HCC risk in PSC
-
by Doug Brunk
Investigators followed 3,071 patients for a mean of 12.5 years.
Positive trends in chronic HCV mortality
-
by Doug Brunk
“DAAs have revolutionized the management of HCV by making it a curable disease.”
ALD-related HCC mortality surges
-
by Doug Brunk
The findings underscore the urgent need for targeted prevention strategies among high-risk group.
Approach to weight management in GI practice
-
by Colleen R. Kelly, MD
As gastroenterologists, we treat a number of conditions that are caused or worsened by obesity.
Bringing HCC patients hope through trials, advanced treatments
-
by Jennifer Lubell
For Reena Salgia, MD, the most rewarding part about working with patients with HCC is being there for their entire journey,
Statins and the liver: Not harmful and perhaps beneficial
-
by Paul Martin, MD, Lawrence S. Friedman, MD